Antipsychotics and Substance Use: A Fresh Look at Old Drugs
Oct 24, 2023
auto_awesome
This podcast explores the impact of antipsychotic switching on substance use in schizophrenia. It discusses the potential benefits of switching from risperidone to clozapine based on insights from national cohorts. The podcast also delves into a study comparing the effects of clozapine and risperidone on craving and brain activation in patients with dual diagnosis. It suggests that switching to clozapine may lead to better outcomes. The potential impact of switching antipsychotic medication on substance use in schizophrenia is further explored, with previous studies indicating a higher likelihood of alcohol remission with clozapine use. However, the side effects of clozapine should be considered.
Patients using clozapine are more likely to remit from alcohol use than those using other antipsychotics.
Switching from risperidone to clozapine might lead to a better outcome for patients with schizophrenia and substance use disorder.
Deep dives
The potential impact of switching from risperidone to clozapine on substance use
Previous studies have found that patients using clozapine are more likely to remit from alcohol use than those using other antipsychotics. Also intriguing is a study showing how brain activation in cannabis users may be influenced by the type of antipsychotic medication used. The implication here is that D2 blockade, which is relatively low with clozapine and higher with most other antipsychotics, could actually create a craving for cannabis. However, this idea remains largely speculative.
Clozapine's potential as a protective agent against substance use in schizophrenia
This new epidemiologic study further supports the concept that clozapine may offer some protection against developing a substance use problem in patients with schizophrenia. If other means of addressing a dual diagnosis fail, switching from risperidone to clozapine might lead to a better outcome. However, it's important to consider that clozapine has significant metabolic and anticholinergic side effects. With new weight management drugs like GLP1 agonists emerging, the risk-benefit ratio of clozapine could soon improve.
Could antipsychotic switching impact substance use in schizophrenia? In this episode, Dr. Jim Phelps explores the impact of antipsychotics on patients with schizophrenia and substance use disorder. He includes insights from national cohorts and clinical cases and delves into the potential effects of changing from risperidone to clozapine.
Faculty: Jim Phelps, M.D. Host: Richard Seeber, M.D.